Kennedy Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Kennedy Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-250,804	Closed	-$3.17M	–	719
2020 Q4	$3.17M	Sell	250,804 -7,729	-3%	-$88.1K	0.07%	438
2020 Q3	$2.54M	Sell	258,533 -5,425	-2%	-$53.5K	0.07%	451
2020 Q2	$2.63M	Buy	263,958 +3,596	+1%	+$34.5K	0.08%	453
2020 Q1	$2.3M	Buy	260,362 +165,665	+175%	+$1.63M	0.08%	426
2019 Q4	$874K	Sell	94,697 -1,680	-2%	-$11.9K	0.02%	626
2019 Q3	$567K	Sell	96,377 -2,729	-3%	-$29K	0.01%	628
2019 Q2	$1.19M	Buy	+99,106	New	+$1.07M	0.03%	591

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's CNCE Position: Q1 2021 in Review

Kennedy Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 250,804 shares — an estimated $3.17M sold.

Kennedy Capital Management first reported a position in CNCE in Q2 2019 and held it in 7 quarters. The position peaked at $3.17M in Q4 2020. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

Kennedy Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Kennedy Capital Management sold 250,804 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $3.17M.
Kennedy Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2019 and held it in 7 quarters.
Kennedy Capital Management's Concert Pharmaceuticals, Inc. position peaked at $3.17M in Q4 2020.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on Kennedy Capital Management's 13F filing for Q1 2021, filed 14 May 2021.